Insulin requirement profiles and related factors of insulin pump therapy in patients with type 2 diabetes
Continuous subcutaneous insulin infusion (CSII) is an effective therapy to control hyperglycemia in both patients with type 1 diabetes and type 2 diabetes. However, there is little data investigating the insulin dose setting during CSII therapy in type 2 diabetes to achieve optimal glycemic control and avoid the risk of hypoglycemia. Thus, this study is aimed to assess the dose characteristics of insulin requirement and explore the related clinical factors in patients with type 2 diabetes who were treated with CSII. A total of 327 patients (195 males) aged 52.9±12.5 years old were included in this study. Patients were treated with CSII to achieve the target fasting capillary blood glucose (4.4–7.0 mmol L-1) and 2-h postprandial capillary blood glucose (4.4–10.0 mmol L-1) by adjusting insulin infusion according to the seven-point capillary blood glucose profiles. Total daily insulin dose (TDD), total daily insulin dose per kilogram (TDD kg-1) and the ratio of total basal insulin dose (TBD) to TDD (%TBa) were calculated after patients achieved the glucose targets for at least 3 days via 1–2 weeks of CSII treatment. And insulin dose, insulin dosing patterns and the relevant clinical factors were analyzed. The mean ratio of basal/bolus insulin distribution of all patients was 40%:60%. Patients with central obesity needed more TDD (51.3±17.1 U versus 43.5±14.0 U, P<0.05) and TDD kg-1 (0.8±0.3 U kg-1 versus 0.7±0.2 U kg-1, P<0.05) than those without central obesity. Pearson's correlation analysis demonstrated that TDD was positively correlated with body mass index (BMI), waist circumference (WC), baseline fasting plasma glucose (FPG), fasting C-peptide level, 2 h-postprandial C-peptide level and time to achieve glycemic target (all P<0.05); TDD kg-1 was positively correlated with waist-to-hip ratio (WHR), baseline FPG, glycosylated hemoglobin A1c (HbA1c), fasting C-peptide level and time to achieve glycemic target, and negatively correlated with BMI (all P<0.05). Multiple linear regression analyses revealed that BMI (β=1.796, P<0.01), WC (β=0.709, P<0.01), baseline FPG (β=1.459, P<0.01) and HbA1c (β=0.930, P=0.021) were independently related to TDD. Gender (β=-0.107, P=0.003), WC (β=0.005, P=0.029), baseline FPG (β=0.025, P<0.01) and HbA1c (β=0.016, P=0.007) were independently associated with TDD kg-1. Gender (β=-0.015, P=0.048) and disease duration (β=0.134, P=0.029) were independently associated with %TBa. %TBa is around 40% in Chinese patients with type 2 diabetes treated with CSII when glycemic control is achieved. In addition to body weight or BMI, WC and glucose levels before CSII should be considered to set TDD. Patients with central obesity or poor glycemic control might need more TDD. Higher %TBa should be considered in female patients or patients with longer disease duration.
Keywordcontinuous subcutaneous insulin infusion insulin requirement profiles type 2 diabetes
Unable to display preview. Download preview PDF.
This work was supported by the National Key Research and Development Program of China (2016YFC1304801), the National Natural Science Foundation of Guangdong Province (2018A030313915), Science and Technology Planning Project of Guangzhou (201508020027) and Medical Scientific Research Foundation of Guangdong Province of China (A2018286).
- Aronson, R., Reznik, Y., Conget, I., Castañeda, J.A., Runzis, S., Lee, S.W., Cohen, O., and Cohen, O. (2016) Sustained efficacy of insulin pump therapy compared with multiple daily injections in type 2 diabetes: 12-month data from the OpT2mise randomized trial. Diabetes Obes Metab 18, 500–507.CrossRefGoogle Scholar
- Festa, A., Williams, K., Hanley, A.J.G., and Haffner, S.M. (2008) Cell dysfunction in subjects with impaired glucose tolerance and early type 2 diabetes: Comparison of surrogate markers with first-phase insulin secretion from an intravenous glucose tolerance test. Diabetes 57, 1638–1644.CrossRefGoogle Scholar
- Grunberger, G., Abelseth, J.M., Bailey, T.S., Bode, B.W., Handelsman, Y., Hellman, R., Jovanovič L., Lane, W.S., Raskin, P., Tamborlane, W.V., et al. (2014) Consensus statement by the American association of clinical endocrinologists/american college of endocrinology insulin pump management task force. Endocrine Practice 20, 463–489.CrossRefGoogle Scholar
- Herman, W.H., Dungan, K.M., Wolffenbuttel, B.H.R., Buse, J.B., Fahrbach, J.L., Jiang, H., and Martin, S. (2009) Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes. J Clin Endocrinol Metab 94, 1689–1694.CrossRefGoogle Scholar
- Holterhus, P.M., Bokelmann, J., Riepe, F., Heidtmann, B., Wagner, V., Rami-Merhar, B., Kapellen, T., Raile, K., Quester, W., Holl, R.W., et al. (2013) Predicting the optimal basal insulin infusion pattern in children and adolescents on insulin pumps. Diabetes Care 36, 1507–1511.CrossRefGoogle Scholar
- Kuroda, A., Kaneto, H., Yasuda, T., Matsuhisa, M., Miyashita, K., Fujiki, N., Fujisawa, K., Yamamoto, T., Takahara, M., Sakamoto, F., et al. (2011) Basal insulin requirement is 30% of the total daily insulin dose in type 1 diabetic patients who use the insulin pump. Diabetes Care 34, 1089–1090.CrossRefGoogle Scholar
- Ma J, Zhou H, Xu H, Chen X, Teng X, Liu Q, Liu W. (2016) The initial assessment of daily insulin dose in Chinese newly diagnosed type 2 diabetes. J Diabetes Res, 2016, 7245947.Google Scholar
- Noh, Y.H., Lee, W.J., Kim, K.A., Lim, I., Lee, J.H., Lee, J.H., Kim, S., and Choi, S.B. (2010) Insulin requirement profiles of patients with type 2 diabetes after achieving stabilized glycemic control with short-term continuous subcutaneous insulin infusion. Diabetes Tech Therap 12, 271–281.CrossRefGoogle Scholar
- Tatsumi, Y., Watanabe, M., Nakai, M., Kokubo, Y., Higashiyama, A., Nishimura, K., Kobayashi, T., Takegami, M., Nakao, Y.M., Watanabe, T., et al. (2015) Changes in waist circumference and the incidence of type 2 diabetes in community-dwelling men and women: The Suita study. J Epidemiol 25, 489–495.CrossRefGoogle Scholar
- Tsukiyama, H., Nagai, Y., Matsubara, F., Shimizu, H., Iwamoto, T., Yamanouchi, E., Sada, Y., Kato, H., Ohta, A., and Tanaka, Y. (2016) Proposed cut-off values of the waist circumference for metabolic syndrome based on visceral fat volume in a Japanese population. J Diabetes Investig 7, 587–593.CrossRefGoogle Scholar
- Weng, J., Li, Y., Xu, W., Shi, L., Zhang, Q., Zhu, D., Hu, Y., Zhou, Z., Yan, X., Tian, H., et al. (2008) Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: A multicentre randomised parallel-group trial. Lancet 371, 1753–1760.CrossRefGoogle Scholar